A group of ministers (GoM) has put its weight behind a market-based pricing mechanism for 348 essential drugs, a departure from the current practice of pricing a dated list of 74 drugs based on their manufacturing costs. The GoM decision might suggest that closure to a long-pending issue isn't far away. But to my mind, … Continue reading India and drug pricing : the illusion of closure
Apothecurry 